Jaspr Health Expands & Extends Pilot Testing of Industry’s 1st Digital Suicide Care Platform to Help Save Lives

Extended to Primary Care with National Institute on Alcohol Abuse and Alcoholism (NIAAA) Funding; Allina Health Partnership Expands Emergency Department Partnerships

Jaspr Health, the first scientifically-validated, suicide-specific digital care platform, today announced the expansion of its pilot program in Emergency Departments (EDs) via a partnership with Allina Health, along with the expansion of use to primary care settings via a $2.1M grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Jaspr Health tablet and mobile applications bolster capacity and speed recommended, evidence-based care – assessments and interventions that have been rigorously evaluated and shown to produce positive impacts – with its automated assistant’s on-demand guided assessments, crisis stability planning, hope-inspiring videos of survivors with lived experiences and a library of coping skills.

Staffing shortages across the nation have made it difficult for EDs and primary care clinics to provide suicide care to those in need. Today, the lack of qualified ED staff can delay care of a person in suicide crisis by as much as 12 hours. Even before COVID, behavioral health emergency care took three times longer than other health emergencies. When finally received, this care is often below-standard for patients and expensive for healthcare systems.

“EDs have seen an overwhelming increase in behavior health emergencies over the last decade – a staggering 14 million per year and growing at 12 percent. Exactly as with a stroke or heart attack patient, the immediate, and the right emergency care, can save the life of a person in suicide crisis,” said Dr. Kelly Koerner, Jaspr Health CEO and founder. “Jaspr was designed to support providers and enable them to reliably deliver the right care quickly. We are thrilled to extend our success in the ED to primary care and expand features to help people with problem drinking.”

Jaspr’s Solution

Jaspr Health is patient-endorsed, peer-reviewed and rigorously tested. The applications were designed by suicide science experts, people with lived experience, and leading health systems to help save lives by providing immediate, compassionate suicide care. Using standardized, evidence-based protocols to help stabilize patients, including suicide risk assessments and crisis stability planning, hospitals can decrease downstream costs and ensure continuity of care.

With integration into electronic health records, workloads are decreased and patient engagements can be optimized and adjusted to improve quality. The solution also offers ED staff the just-in-time training critical to building confidence and skill sets to effectively help patients in crisis. Overall, Jaspr Health aims to improve the patient experience, while helping health systems reduce risks and costs, without any increased burden on healthcare providers.

In National Institute of Health (NIH) funded clinical trials, Jaspr outperformed traditional care in the ER, enabling increased access to evidence-based, suicide-specific interventions, increased ability for patients to cope with suicidal thoughts, decreased patient distress and agitation, and increased reports from patients of learning skills to regulate their emotions. The solution is currently being piloted in nearly 20 EDs across the nation, and will expand testing into primary care clinics as well as to individuals with alcohol use disorders, often associated with both an exponential increase in suicide risk and interference in suicide prevention efforts.

For more information on the features and benefits of Jaspr Health’s tablet and mobile applications, click here.

Jaspr Health Partnerships

The company’s new partnership with Allina Health will help reduce the growing rate of suicide throughout the Minnesota and Western Wisconsin area. This five-year partnership will include the use of Jaspr Health for people acutely at risk for suicide and seeking psychiatric crisis services from one of Allina Health’s 12 EDs.

The grant from NIAAA generates the funding necessary for Jaspr to extend trials into primary care clinics, and expand to include patients with alcohol use disorders, which result in a tenfold increase of suicide risk and interfere with suicide prevention efforts.

These announcements follow on the heels of its relationship with the Zero Suicide Institute to integrate awareness, education and support to help save lives. This Fall, the organizations will jointly launch new educational programs and content for health systems highlighting how digital technology can significantly improve the standardization of compassionate, personalized and evidence-based care.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy